Literature DB >> 26810647

Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center.

David A Stevens1, Richard B Moss2, Cathy Hernandez2, Karl V Clemons3, Marife Martinez4.   

Abstract

Studies of cystic fibrosis (CF) patient exacerbations attributed toPseudomonas aeruginosainfection have indicated a lack of correlation of outcome within vitrosusceptibility results. One explanation is that the media used for testing do not mimic the airway milieu, resulting in incorrect conclusions. Therefore, media have been devised to mimic CF sputum.Aspergillus fumigatusis the leading fungal pathogen in CF, and susceptibility testing is also used to decide therapeutic choices. We assessed whether media designed to mimic CF sputa would give different fungal susceptibility results than those of classical methods, assaying voriconazole, the most utilized anti-Aspergillusdrug in this setting, and 30 CFAspergillusisolates. The frequency of marked resistance (defined as an MIC of >4 μg/ml) in our CF unit by classical methods is 7%. Studies performed with classical methods and with digested sputum medium, synthetic sputum medium, and artificial sputum medium revealed prominent differences inAspergillussusceptibility results, as well as growth rate, with each medium. Clinical correlative studies are required to determine which results are most useful in predicting outcome. Comparison of MICs with non-CF isolates also indicated the CF isolates were generally more resistant.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26810647      PMCID: PMC4808157          DOI: 10.1128/AAC.02649-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

2.  High-resolution genotyping of Aspergillus fumigatus isolates recovered from chronically colonised patients with cystic fibrosis.

Authors:  L M E Vanhee; F Symoens; J-P Bouchara; H J Nelis; T Coenye
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-06       Impact factor: 3.267

3.  The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis.

Authors:  Reshma Amin; Annie Dupuis; Shawn D Aaron; Felix Ratjen
Journal:  Chest       Date:  2009-06-30       Impact factor: 9.410

4.  Aspergillus bronchitis in cystic fibrosis.

Authors:  David Shoseyov; Keith G Brownlee; Steven P Conway; Eitan Kerem
Journal:  Chest       Date:  2006-07       Impact factor: 9.410

5.  Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.

Authors:  Wei Xiao; Yao-Pi Hsu; Akitoshi Ishizaka; Teruo Kirikae; Richard B Moss
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

6.  Susceptibility to five antifungals of Aspergillus fumigatus strains isolated from chronically colonised cystic fibrosis patients receiving azole therapy.

Authors:  Adelina Amorim; Luísa Guedes-Vaz; Ricardo Araujo
Journal:  Int J Antimicrob Agents       Date:  2010-02-09       Impact factor: 5.283

7.  Molecular typing and colonization patterns of Aspergillus fumigatus in patients with cystic fibrosis.

Authors:  Hanneke A de Valk; Corné H W Klaassen; Jan-Bart Yntema; Alexandra Hebestreit; Marc Seidler; Gerhard Haase; Frank-Michael Müller; Jacques F G M Meis
Journal:  J Cyst Fibros       Date:  2008-11-28       Impact factor: 5.482

8.  Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?

Authors:  Paul E Verweij; Eveline Snelders; Gert H J Kema; Emilia Mellado; Willem J G Melchers
Journal:  Lancet Infect Dis       Date:  2009-12       Impact factor: 25.071

Review 9.  Azole-resistance in Aspergillus: proposed nomenclature and breakpoints.

Authors:  Paul E Verweij; Susan J Howard; Willem J G Melchers; David W Denning
Journal:  Drug Resist Updat       Date:  2009-10-29       Impact factor: 18.500

10.  Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.

Authors:  Susan J Howard; Dasa Cerar; Michael J Anderson; Ahmed Albarrag; Matthew C Fisher; Alessandro C Pasqualotto; Michel Laverdiere; Maiken C Arendrup; David S Perlin; David W Denning
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

View more
  7 in total

1.  Susceptibility of Candida albicans from Cystic Fibrosis Patients.

Authors:  Raquel Sabino; Elisabete Carolino; Richard B Moss; Niaz Banaei; Cristina Verissimo; David A Stevens
Journal:  Mycopathologia       Date:  2017-04-18       Impact factor: 2.574

Review 2.  Azole Resistance in Aspergillus fumigatus in Patients with Cystic Fibrosis: A Matter of Concern?

Authors:  A Hamprecht; F Morio; O Bader; P Le Pape; J Steinmann; E Dannaoui
Journal:  Mycopathologia       Date:  2017-06-26       Impact factor: 2.574

3.  Are Cystic Fibrosis Aspergillus fumigatus Isolates Different? Intermicrobial Interactions with Pseudomonas.

Authors:  Hasan Nazik; Richard B Moss; Vyshnavi Karna; Karl V Clemons; Niaz Banaei; Kevin Cohen; Varun Choudhary; David A Stevens
Journal:  Mycopathologia       Date:  2016-11-07       Impact factor: 2.574

Review 4.  Emerging Fungal Threats in Cystic Fibrosis.

Authors:  C Schwarz; P Eschenhagen; J P Bouchara
Journal:  Mycopathologia       Date:  2021-07-28       Impact factor: 2.574

5.  Pseudomonas aeruginosa Virulence Factors Support Voriconazole Effects on Aspergillus fumigatus.

Authors:  Gabriele Sass; Pallabi Shrestha; David A Stevens
Journal:  Pathogens       Date:  2021-04-26

Review 6.  Cystic fibrosis lung environment and Pseudomonas aeruginosa infection.

Authors:  Anjali Y Bhagirath; Yanqi Li; Deepti Somayajula; Maryam Dadashi; Sara Badr; Kangmin Duan
Journal:  BMC Pulm Med       Date:  2016-12-05       Impact factor: 3.317

7.  Impact of Artificial Sputum Medium Formulation on Pseudomonas aeruginosa Secondary Metabolite Production.

Authors:  Rachel L Neve; Brent D Carrillo; Vanessa V Phelan
Journal:  J Bacteriol       Date:  2021-08-16       Impact factor: 3.490

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.